Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
Revisit the OncLive On Air Episodes From February 2024
State of the Science Summit - Hematology: Chaired by Martha Arellano, MD
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
European Commission Approves Cilta-Cel for R/R Myeloma After at Least 1 Prior Line of Therapy
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma